ESTRO 临床实践指南:NSCLC 高剂量胸部再程放疗
该 ESTRO 指南由欧洲与北美胸部放疗及再程放疗多学科专家组采用改良 Delphi 共识流程制定,围绕患者选择、分期、靶区勾画、剂量分割、计划实施、累积剂量评估、联合系统治疗与随访共 8 个关键问题形成 42 条共识推荐,强调个体化剂量分割与累积危及器官约束平衡,联合系统治疗推荐因证据有限仍为条件性。
要点
- 强调严格患者选择与全面分期后再行高剂量胸部再程放疗。
- 靶区勾画需整合既往治疗数据,剂量分割应个体化并评估累积危及器官剂量。
- 推荐高适形图像引导技术;再程放疗联合系统治疗推荐仍为条件性。
核心结论
- 在缺乏高质量随机证据的情况下,该指南以共识推荐支持多学科决策,并指出未来临床研究重点。
研究设计与样本
- 由欧洲与北美放射肿瘤学、临床肿瘤学与医学物理专家组成的国际多学科专家组制定。
- 采用结构化改良 Delphi 共识流程,围绕预设的 8 个关键临床问题形成并 refine 推荐与声明。
主要发现
- 共形成 42 条共识推荐与声明,覆盖患者选择、诊断检查、靶区定义、剂量分割、计划与实施、累积剂量评估、联合系统治疗及随访。
关键数值与推荐
- 推荐强调严格患者选择、全面分期、整合既往治疗数据的精确靶区勾画,以及平衡肿瘤控制与累积危及器官约束的个体化剂量分割。
- 高度适形图像引导技术与结构化累积剂量评估被视为安全实施的必要条件。
- 再程放疗联合系统治疗的指导因证据有限仍为条件性推荐。
- 提出标准化随访策略以监测不良反应与疾病控制。
临床怎么用
- 用于指导 NSCLC 高剂量胸部再程放疗的患者选择、靶区勾画、剂量分割、计划实施与随访。
- 推荐以多学科团队决策方式应用,并作为现有再程放疗技术、方法与工作流共识文件的补充。
局限性
- 高质量随机证据有限,联合系统治疗等部分推荐为条件性共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High-dose thoracic reirradiation is increasingly used in clinical practice for patients with non-small cell lung cancer (NSCLC) in a variety of clinical scenarios ranging from locoregional recurrence to selected metastatic settings. The treatment goals of thoracic reirradiation include durable local control, symptom palliation, and potential cure. Despite growing clinical adoption, high-quality randomised evidence guiding patient selection, treatment delivery, and integration with systemic therapy remains limited. This ESTRO- clinical practice guideline aims to provide expert consensus recommendations for high-dose thoracic reirradiation in NSCLC based on the available literature and structured expert agreement. MATERIALS AND METHODS: The guideline was developed by an international, interdisciplinary panel of experts in thoracic radiation oncology and reirradiation, including specialists in radiation oncology, clinical oncology, and medical physics from Europe and North America. A structured modified Delphi consensus process was used to derive and refine recommendations and statements addressing predefined key clinical questions covering patient selection, diagnostic workup, target definition, dose and fractionation, treatment planning and delivery, cumulative dose assessment, combination with systemic therapy, and follow-up. RESULTS: A total of 42 consensus recommendations and statements were derived across eight key questions. Recommendations emphasise careful patient selection, comprehensive staging, precise target delineation integrating prior treatment data, and individualized dose and fractionation balancing tumour control with cumulative organ at risk constraints. Highly conformal image-guided techniques and structured cumulative dose assessment were considered essential for safe delivery. Guidance on combining reirradiation with systemic therapy remains conditional due to limited evidence, and standardised follow-up strategies were proposed to monitor side effects and disease control. CONCLUSIONS: This ESTRO guideline provides consensus-based recommendations to inform clinical practice for high-dose thoracic reirradiation in NSCLC and is intended to complement existing consensus documents addressing technical, methodological, and workflow aspects of reirradiation. In the absence of robust prospective data, these recommendations support multidisciplinary decision-making while highlighting priorities for future clinical research.
引用
- Andratschke N, Willmann J, Ippolito E, et al. ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer. Radiother Oncol. 2026. PMID: 42468604. doi:10.1016/j.radonc.2026.111707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。